Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Gionata Fiorino, Flavio Caprioli, Marco Daperno, Filippo Mocciaro, Mariabeatrice Principi, Angelo Viscido, Massimo Claudio Fantini, Ambrogio Orlando, Claudio Papi, Vito Annese, Silvio Danese, Maurizio Vecchi, Fernando Rizzello, Alessandro Armuzzi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines Agency. Biosimilars present great potential in terms of cost saving and possible consequential reinvestment in the health care system. The increasing knowledge about the process of biosimilar development and use in IBD and the publication of many prospective clinical studies and real-life clinical experiences have progressively changed the point of view of IBD physicians. In the present position paper, the Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars.

Original languageEnglish
Pages (from-to)632-639
JournalDigestive and Liver Disease
Volume51
Issue number5
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Patient Education
Publications
Tumor Necrosis Factor-alpha
Prospective Studies
Delivery of Health Care
Physicians
Safety
Costs and Cost Analysis

Keywords

  • Anti-TNFα
  • Biosimilars
  • Crohn's disease
  • Inflammatory bowel disease
  • Tumor necrosis factor alpha
  • Ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Use of biosimilars in inflammatory bowel disease : A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). / Fiorino, Gionata; Caprioli, Flavio; Daperno, Marco; Mocciaro, Filippo; Principi, Mariabeatrice; Viscido, Angelo; Fantini, Massimo Claudio; Orlando, Ambrogio; Papi, Claudio; Annese, Vito; Danese, Silvio; Vecchi, Maurizio; Rizzello, Fernando; Armuzzi, Alessandro.

In: Digestive and Liver Disease, Vol. 51, No. 5, 01.01.2019, p. 632-639.

Research output: Contribution to journalArticle

Fiorino, Gionata ; Caprioli, Flavio ; Daperno, Marco ; Mocciaro, Filippo ; Principi, Mariabeatrice ; Viscido, Angelo ; Fantini, Massimo Claudio ; Orlando, Ambrogio ; Papi, Claudio ; Annese, Vito ; Danese, Silvio ; Vecchi, Maurizio ; Rizzello, Fernando ; Armuzzi, Alessandro. / Use of biosimilars in inflammatory bowel disease : A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). In: Digestive and Liver Disease. 2019 ; Vol. 51, No. 5. pp. 632-639.
@article{9b580e3048b44a7f9dcc9eaf069b85dd,
title = "Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)",
abstract = "The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines Agency. Biosimilars present great potential in terms of cost saving and possible consequential reinvestment in the health care system. The increasing knowledge about the process of biosimilar development and use in IBD and the publication of many prospective clinical studies and real-life clinical experiences have progressively changed the point of view of IBD physicians. In the present position paper, the Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars.",
keywords = "Anti-TNFα, Biosimilars, Crohn's disease, Inflammatory bowel disease, Tumor necrosis factor alpha, Ulcerative colitis",
author = "Gionata Fiorino and Flavio Caprioli and Marco Daperno and Filippo Mocciaro and Mariabeatrice Principi and Angelo Viscido and Fantini, {Massimo Claudio} and Ambrogio Orlando and Claudio Papi and Vito Annese and Silvio Danese and Maurizio Vecchi and Fernando Rizzello and Alessandro Armuzzi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.dld.2019.02.004",
language = "English",
volume = "51",
pages = "632--639",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Use of biosimilars in inflammatory bowel disease

T2 - A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

AU - Fiorino, Gionata

AU - Caprioli, Flavio

AU - Daperno, Marco

AU - Mocciaro, Filippo

AU - Principi, Mariabeatrice

AU - Viscido, Angelo

AU - Fantini, Massimo Claudio

AU - Orlando, Ambrogio

AU - Papi, Claudio

AU - Annese, Vito

AU - Danese, Silvio

AU - Vecchi, Maurizio

AU - Rizzello, Fernando

AU - Armuzzi, Alessandro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines Agency. Biosimilars present great potential in terms of cost saving and possible consequential reinvestment in the health care system. The increasing knowledge about the process of biosimilar development and use in IBD and the publication of many prospective clinical studies and real-life clinical experiences have progressively changed the point of view of IBD physicians. In the present position paper, the Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars.

AB - The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines Agency. Biosimilars present great potential in terms of cost saving and possible consequential reinvestment in the health care system. The increasing knowledge about the process of biosimilar development and use in IBD and the publication of many prospective clinical studies and real-life clinical experiences have progressively changed the point of view of IBD physicians. In the present position paper, the Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars.

KW - Anti-TNFα

KW - Biosimilars

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Tumor necrosis factor alpha

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85062593056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062593056&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2019.02.004

DO - 10.1016/j.dld.2019.02.004

M3 - Article

AN - SCOPUS:85062593056

VL - 51

SP - 632

EP - 639

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 5

ER -